Role of monocyte chemoattractant protein-1, tumor necrosis factor-α and interleukin-6 in the control of malignant pleural effusion and survival in patients with primary lung adenocarcinoma

International Journal of Biological Markers

Volumn 27, Issue 2, 2012, Pages 118-124

  Qian, Qian ^a   Sun, Wen Kui ^b   Zhan, Ping ^a   Zhang, Yu ^a   Song, Yong ^b   Yu, Li Ke ^a  

^a NANJING CHEST HOSPITAL   (China)

^b JINLING HOSPITAL   (China)

Author keywords

Interleukin 6; Lung adenocarcinoma; Malignant pleural effusion; Monocyte chemoattractant protein 1; Survival; Tumor necrosis factor a

Indexed keywords

INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATINUM; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHINESE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PLEURA EFFUSION; PLEURODESIS; PREDICTIVE VALUE; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; SCLEROTHERAPY; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871085233     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2012.9197     Document Type: Article

References (38)

1. Light RW. Clinical practice. Pleural effusion. N Engl J Med 2002; 346: 1971-1977.
2. Antunes G, Neville E, Duffy J, Ali N. BTS guidelines for the management of malignant pleural effusions. Thorax 2003; 58 Suppl 2: ii29-38.
3. Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 1997; 3: 47-50.
4. Naito T, Satoh H, Ishikawa H, et al. Pleural effusion as a significant prognostic factor in non-small cell lung cancer. Anticancer Res 1997; 17: 4743-4746.
5. Light RW. Talc for pleurodesis. Chest 2002; 122: 1506-1508.
6. Maskell NA, Lee YC, Gleeson FV, Hedley EL, Pengelly G, Davies RJ. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004; 170: 377-382.
7. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000; 162: 1987-2001.
8. Lee YC, Light RW. Management of malignant pleural effusions. Respirology 2004; 9: 148-156.
9. Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of mono-cytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol 2001; 166: 6483-6490.
10. Conti I, Rollins BJ. CCL2 (monocyte chemoattractant pro-tein-1) and cancer. Semin Cancer Biol 2004; 14: 149-154.
11. Negus RP, Stamp GW, Relf MG, et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 1995; 95: 2391-2396.
12. Arenberg DA, Keane MP, DiGiovine B, et al. Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol Immunother 2000; 49: 63-70.
13. Ueno T, Toi M, Saji H, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, an-giogenesis, and survival in human breast cancer. Clin Cancer Res 2000; 6: 3282-3289.
14. Salcedo R, Ponce ML, Young HA, et al. Human endothe-lial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000; 96: 34-40.
15. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3: 745-756.
16. Shimomoto H, Hasegawa Y, Nozaki Y, et al. Expression of tumor necrosis factor receptors in human lung cancer cells and normal lung tissues. Am J Respir Cell Mol Biol 1995; 13: 271-278.
17. Kulbe H, Thompson R, Wilson JL, et al. The inflammatory cytokine tumor necrosis factor-alpha generates an auto-crine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 2007; 67: 585-592.
18. Hamed EA, El-Noweihi AM, Mohamed AZ, Mahmoud A. Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions. Respirol-ogy 2004; 9: 81-86.
19. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest 2000; 117: 1162-1172.
20. Elias JA, Freundlich B, Kern JA, Rosenbloom J. Cytokine networks in the regulation of inflammation and fibrosis in the lung. Chest 1990; 97: 1439-1445.
21. Welsh JB, Sapinoso LM, Kern SG, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA 2003; 100: 3410-3415.
22. Agrenius V, Gustafsson LE, Widstrom O. Tumour necrosis factor-alpha and nitric oxide, determined as nitrite, in malignant pleural effusion. Respir Med 1994; 88: 743-748.
23. Lin CC, Liu CC, Lin CY. Changes in cell population and tumor necrosis factor, interleukin-6, and interleukin-8 in malignant pleural effusions after treatment with intrapleural tetracycline. Am Rev Respir Dis 1993; 147: 1503-1506.
24. Su WC, Lai WW, Chen HH, et al. Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion. A pilot study. Oncology 2003; 64: 18-24.
25. Neragi-Miandoab S. Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer 2006; 54: 1-9.
26. Musani AI. Treatment options for malignant pleural effusion. Curr Opin Pulm Med 2009; 15: 380-387.
27. Perng RP, Chen YM, Wu MF, et al. Phase II trial of intrapleu-ral paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions. Respir Med 1998; 92: 473-479.
28. Brown CE, Vishwanath RP, Aguilar B, et al. Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol 2007; 179: 3332-3341.
29. Wang T, Dai H, Wan N, Moore Y, Dai Z. The role for monocyte chemoattractant protein-1 in the generation and function of memory CD8+ T cells. J Immunol 2008; 180: 2886-2893.
30. Walter S, Bottazzi B, Govoni D, Colotta F, Mantovani A. Macrophage infiltration and growth of sarcoma clones expressing different amounts of monocyte chemotactic pro-tein/JE. Int J Cancer 1991; 49: 431-435.
31. Manome Y, Wen PY, Hershowitz A, et al. Monocyte che-moattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors. Cancer Immunol Immunother 1995; 41: 227-235.
32. Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 2007; 9: 556-562.
33. Fridlender ZG, Buchlis G, Kapoor V, et al. CCL2 blockade augments cancer immunotherapy. Cancer Res 2010; 70: 109-118.
34. Stathopoulos GT, Psallidas I, Moustaki A, et al. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst 2008; 100: 1464-1476.
35. Kuroda T, Kitadai Y, Tanaka S, et al. Monocyte chemoat-tractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin Cancer Res 2005; 11: 7629-7636.
36. Stathopoulos GT, Kollintza A, Moschos C, et al. Tumor necrosis factor-alpha promotes malignant pleural effusion. Cancer Res 2007; 67: 9825-9834.
37. Yeh HH, Lai WW, Chen HH, Liu HS, Su WC. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 2006; 25: 4300-4309.
38. Loberg RD, Day LL, Harwood J, et al. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 2006; 8: 578-586.